Targeting castration-resistant prostate cancer with a novel RORγ antagonist elaiophylin

Targeting castration-resistant prostate cancer with a novel RORγ antagonist elaiophylin

Prostate cancer (PCa) patients who progress to metastatic castration-resistant PCa (mCRPC) mostly have poor outcomes due to the lack of effective therapies. Our recent study established the orphan nuclear receptor RORγ as a novel therapeutic target for CRPC. Here, we reveal that elaiophylin (Elai),...

Full description

Bibliographic Details
Main Authors: Jianwei Zheng, Junfeng Wang, Qian Wang, Hongye Zou, Hong Wang, Zhenhua Zhang, Jianghe Chen, Qianqian Wang, Panxia Wang, Yueshan Zhao, Jing Lu, Xiaolei Zhang, Songtao Xiang, Haibin Wang, Jinping Lei, Hong-Wu Chen, Peiqing Liu, Yonghong Liu, Fanghai Han, Junjian Wang
Format: Article
Language:English
Published: Elsevier 2020-12-01
Series:Acta Pharmaceutica Sinica B
Subjects:
RORγ
Castration-resistant prostate cancer
Nuclear receptor
Antagonist
Elaiophylin
Online Access:http://www.sciencedirect.com/science/article/pii/S2211383520306274

Internet

http://www.sciencedirect.com/science/article/pii/S2211383520306274

Similar Items